a decreasing trendP < 0.05
With ongoing treatment, both groups showed a decreasing trend in B cell proportions, with statistically significant differences observed within each group (all P < 0.05).
With ongoing treatment, both groups showed a decreasing trend in B cell proportions, with statistically significant differences observed within each group (all P < 0.05).
Although some primary endpoints, like SRI4, did not reach statistical significance, belimumab showed a favorable trend in disease control and a lower incidence of serious adverse events.